HK1244482A1 - 用於治療神經母細胞瘤的組合 - Google Patents

用於治療神經母細胞瘤的組合

Info

Publication number
HK1244482A1
HK1244482A1 HK18103146.7A HK18103146A HK1244482A1 HK 1244482 A1 HK1244482 A1 HK 1244482A1 HK 18103146 A HK18103146 A HK 18103146A HK 1244482 A1 HK1244482 A1 HK 1244482A1
Authority
HK
Hong Kong
Prior art keywords
neuroblastoma
combinations
treatment
Prior art date
Application number
HK18103146.7A
Other languages
English (en)
Inventor
扎卡里．多爾夫．霍恩比
李剛
戴維．衛斯理．安德森
加勒特．M．布羅德
拉迪卡．埃耶
Original Assignee
伊尼塔公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 伊尼塔公司 filed Critical 伊尼塔公司
Publication of HK1244482A1 publication Critical patent/HK1244482A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
HK18103146.7A 2014-12-02 2018-03-05 用於治療神經母細胞瘤的組合 HK1244482A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086366P 2014-12-02 2014-12-02
PCT/US2015/062975 WO2016089760A1 (en) 2014-12-02 2015-11-30 Combinations for the treatment of neuroblastoma

Publications (1)

Publication Number Publication Date
HK1244482A1 true HK1244482A1 (zh) 2018-08-10

Family

ID=56092289

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18103146.7A HK1244482A1 (zh) 2014-12-02 2018-03-05 用於治療神經母細胞瘤的組合
HK18103918.3A HK1244485A1 (zh) 2014-12-02 2018-03-21 用於治療神經母細胞瘤的組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18103918.3A HK1244485A1 (zh) 2014-12-02 2018-03-21 用於治療神經母細胞瘤的組合物

Country Status (9)

Country Link
US (2) US10085979B2 (zh)
EP (1) EP3227276B1 (zh)
JP (1) JP6744309B2 (zh)
KR (1) KR102595599B1 (zh)
CN (1) CN107207471B (zh)
AU (1) AU2015355220B2 (zh)
CA (1) CA2969540C (zh)
HK (2) HK1244482A1 (zh)
WO (1) WO2016089760A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CA2969540C (en) 2014-12-02 2023-03-21 Ignyta, Inc. Combinations for the treatment of neuroblastoma
EP3227686A4 (en) * 2014-12-03 2018-08-29 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
EP3389645A4 (en) 2015-12-18 2019-12-18 Ignyta, Inc. COMBINATIONS FOR TREATING CANCER
IL271759B2 (en) 2017-07-19 2024-01-01 Ignyta Inc Pharmaceutical preparations that include anthraxtinib
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
CN112739691B (zh) 2018-09-03 2023-05-23 泰励生物科技（上海）有限公司 用作抗癌药的trk抑制剂
WO2021088859A1 (zh) * 2019-11-06 2021-05-14 暨南大学 吲唑类化合物及其药用组合物和应用
CN116356034A (zh) * 2023-05-04 2023-06-30 中山大学孙逸仙纪念医院 一种用于预测儿童神经母细胞瘤复发的检测试剂盒及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041489A (ja) 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２
WO1999043302A1 (en) 1998-02-27 1999-09-02 Watson Pharmaceuticals, Inc. Stabilizing composition for pharmaceutical dosage forms
JP2002275068A (ja) 2001-03-16 2002-09-25 Kyowa Hakko Kogyo Co Ltd アポトーシス誘導剤
ATE343575T1 (de) 2001-09-27 2006-11-15 Smithkline Beecham Corp Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
AU2002353186A1 (en) 2001-12-19 2003-06-30 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
WO2004007676A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
NZ539193A (en) 2002-09-05 2008-04-30 Aventis Pharma Sa Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
EP1572200B1 (fr) 2002-12-12 2011-08-17 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
TW200423938A (en) 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
ES2401330T3 (es) 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2007502329A (ja) 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
DK2392564T3 (da) 2003-09-26 2014-01-13 Exelixis Inc c-Met-modulatorer og anvendelsesfremgangsmåder
JP2007508801A (ja) 2003-10-24 2007-04-12 エスバテック・アーゲー 受容体チロシンキナーゼ阻害剤の同定および／または確認のための方法
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
KR20070108881A (ko) 2005-01-27 2007-11-13 교와 핫꼬 고교 가부시끼가이샤 Ｉｇｆ－１ｒ 저해제
WO2006111035A1 (en) 2005-04-21 2006-10-26 Oncalis Ag Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle
AU2006248780B2 (en) 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
JP2009504608A (ja) 2005-08-09 2009-02-05 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ 薬剤耐性肺癌のタンパク質キナーゼ阻害剤への感作
JP2009520825A (ja) 2005-12-20 2009-05-28 武田薬品工業株式会社 グルコキナーゼ活性剤
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
JP5185930B2 (ja) 2006-07-07 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
BRPI0722384A2 (pt) 2006-12-08 2012-06-12 Irm Llc compostos inibidores de proteÍna quinase, composiÇÕes contendo os mesmos bem como seus usos
EP2102190A1 (en) 2006-12-11 2009-09-23 Irm Llc Compounds and compositions as kinase inhibitors
MX2009006401A (es) 2006-12-20 2009-06-23 Nerviano Medical Sciences Srl Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
EP2173338A1 (en) 2007-07-06 2010-04-14 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy
SI2176231T1 (sl) 2007-07-20 2017-01-31 Nerviano Medical Sciences S.R.L. Substituirani indazolni derivati, aktivni kot kinazni inhibitorji
PL2183254T3 (pl) 2007-08-29 2017-10-31 Methylgene Inc Inhibitory aktywności białkowej kinazy tyrozynowej
DK3106463T6 (da) 2008-10-22 2020-02-24 Array Biopharma Inc Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
CN102924479A (zh) 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
WO2013119950A2 (en) 2012-02-08 2013-08-15 Insight Genetics, Inc. Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer
BR112014022106B1 (pt) 2012-03-06 2022-08-02 Pfizer Inc Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças
BR112014028841B1 (pt) * 2012-05-23 2021-01-12 Nerviano Medical Sciences S.R.L. Formas cristalinas 1 e 2, composição farmacêutica, uso da forma cristalina 1 para o tratamento de um estado de doença tratável pela inibição de alk e processo para a preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metilpiperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)- benzamida
US20140107107A1 (en) 2012-09-28 2014-04-17 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2014093750A1 (en) 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
BR112016029012A2 (pt) 2014-06-13 2017-08-22 Oncoethix Gmbh método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
CA2969540C (en) 2014-12-02 2023-03-21 Ignyta, Inc. Combinations for the treatment of neuroblastoma
EP3227686A4 (en) 2014-12-03 2018-08-29 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
AU2016270321B2 (en) 2015-05-29 2020-09-10 Ignyta, Inc. Compositions and methods for treating patients with RTK mutant cells
EP3389645A4 (en) 2015-12-18 2019-12-18 Ignyta, Inc. COMBINATIONS FOR TREATING CANCER
IL271759B2 (en) 2017-07-19 2024-01-01 Ignyta Inc Pharmaceutical preparations that include anthraxtinib

Also Published As

Publication number Publication date
JP6744309B2 (ja) 2020-08-19
CA2969540A1 (en) 2016-06-09
CN107207471B (zh) 2020-06-26
US10357490B2 (en) 2019-07-23
US20170065582A1 (en) 2017-03-09
KR102595599B1 (ko) 2023-11-02
US10085979B2 (en) 2018-10-02
CA2969540C (en) 2023-03-21
EP3227276B1 (en) 2021-09-01
AU2015355220B2 (en) 2020-02-27
JP2018502069A (ja) 2018-01-25
US20190070173A1 (en) 2019-03-07
KR20170094259A (ko) 2017-08-17
EP3227276A1 (en) 2017-10-11
CN107207471A (zh) 2017-09-26
HK1244485A1 (zh) 2018-08-10
WO2016089760A1 (en) 2016-06-09
EP3227276A4 (en) 2018-08-01
AU2015355220A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
HK1232147A1 (zh) 用於治療纖維化的賽尼克韋羅
IL279627A (en) A method for treating depression
HUE053654T2 (hu) FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
HK1244485A1 (zh) 用於治療神經母細胞瘤的組合物
IL248856B (en) New treatment
IL248267B (en) A process for preparing converted cycloserines
SG11201702700UA (en) Methods for the treatment of peri-implantitis
LT3200783T (lt) Eritromelalgijos gydymas
ZA201608307B (en) Process for the purification of l-alpha-glycerophosphorylcholine
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
GB201411027D0 (en) Treatment
HUP1400518A2 (hu) Eljárás tofacitinib elõállítására
IL247443B (en) Process for the preparation of 5-fluorotryptophol
GB201417719D0 (en) New treatment
GB201413317D0 (en) Atheroscierosis treatment
GB201412411D0 (en) Treatment
GB201412410D0 (en) Treatment
GB201408384D0 (en) New treatment
GB201400240D0 (en) Treatment
GB201400241D0 (en) Treatment
GB201400235D0 (en) Treatment
GB201400238D0 (en) Treatment
GB201400239D0 (en) Treatment